Ποια είναι η τιμή για Mabwell (Shanghai) Bioscience Co., Ltd. (688062)

Η τιμή για Mabwell (Shanghai) Bioscience Co., Ltd. (688062) είναι $4.29

Ποια είναι η κεφαλαιοποίηση αγοράς για Mabwell (Shanghai) Bioscience Co., Ltd. (688062)

Η κεφαλαιοποίηση αγοράς για Mabwell (Shanghai) Bioscience Co., Ltd. (688062) είναι $1.71B

Mabwell (Shanghai) Bioscience Co., Ltd. (688062) Τιμή και Κεφαλαιοποίηση Αγοράς

Founded in 2017 and based in Shanghai, China, Mabwell (Shanghai) Bioscience Co., Ltd. is a biopharmaceutical enterprise dedicated to the discovery, development, production, and global commercialization of biological products. The company's comprehensive portfolio addresses a wide spectrum of medical conditions, including autoimmune disorders, various cancers, eye diseases, infectious ailments, and metabolic conditions. A key product is JUNMAIKANG, an Adalimumab injection utilized for autoimmune treatments. Mabwell also maintains a robust clinical pipeline, notably in oncology, where candidates 9MW2821 and 6MW3211 are advancing through Phase II studies, while 9MW2921, 9MW3811, and 7MW3711 are undergoing Phase I trials. Additionally, 8MW0511 has reached Phase III development, alongside 9MW0321. For autoimmune diseases, 9MW1911 and 9MW3811 are in their initial Phase I clinical trials. The company's metabolic product candidates include MAILISHU and 9MW3011. In ophthalmology, 9MW0813 and 9MW0211 are progressing through Phase III. Furthermore, 9MW1411 represents an infectious disease candidate in development.

Η τιμή για 688062	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$13,842.82 $1.71B	NVDA	$5.532T	+322,945.23%
$11,531.93 $1.71B	AAPL	$4.608T	+269,016.64%
$10,249.31 $1.71B	GOOG	$4.096T	+239,084.66%
$9,380.42 $1.71B	MSFT	$3.748T	+218,807.77%
$6,910.29 $1.71B	AMZN	$2.761T	+161,163.01%

Η τιμή για 688062

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$13,842.82 $1.71B